Newsletter | May 14, 2025

05.14.25 -- Big Pharma Insights For Building Biotech Startups

SPONSOR

Viral Vector Upstream Platforms

Cellvento® 4HEK Medium is a chemically defined, animal component-free medium for suspension culture of HEK293 cell lines. Optimized for AAV production, it supports high full capsid titers and works across all stages—cell growth, transfection, and production. Compatible with common transfection reagents like PEI, it's suitable from early development to manufacturing. Learn more about this cell culture media today and request a quote! Learn more.

FEATURED PODCAST

Big Pharma Insights For Building Biotech Startups With Uniquity Bio's Brian Lortie

On this episode of the Business of Biotech, host Ben Comer speaks with Brian Lortie, President and CEO of Uniquity Bio, about his "no jerk" policy and how his experience building teams at GSK, Endo Pharmaceuticals, and Onspira Therapeutics informs his leadership at Uniquity, a clinical-stage immunology startup backed by Blackstone Life Sciences.

INDUSTRY INSIGHTS

The Important Role Of The Study Owner In Guiding The TMF

Learn about the critical role that a study owner plays in maintaining Trial Master File (TMF) oversight, ensuring compliance, and driving collaboration across clinical study teams.

Why The RSM Is The Swiss Army Knife Of Clinical Trial Monitoring

The Regional Site Manager (RSM) monitoring model eliminates numerous clinical trial risks by leveraging efficient, start-to-finish site management by a single, expert point of contact.

Azzur Serves NC Biosciences With "Cleanrooms On Demand"

Find out how a national life sciences service company is helping startups by providing state-of-the-art facilities for product development and manufacturing to accelerate growth and streamline operations.

Patient Experience: Benefits, Strategies, And FAQs

Patient experience encompasses all patient interactions with healthcare providers. Improving communication, setting expectations, and fostering trust enhances safety and overall care satisfaction.

Navigating The 7 Biggest Challenges In Rare Disease Clinical Trials

Discover how partnering with specialized rare disease CROs allows drug sponsors to accelerate treatment development, navigate complexities, and ultimately improve patient outcomes.